L-dopa slows the progression of familial parkinsonism

The putative toxicity of levcodopa has long been debated. Loevodopa is the mainstay of therapy for Parkinson's disease. Sometimes treatment is delayed because of fear of toxicity.

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1999-05, Vol.353 (9167), p.1850-1851
Main Authors: Gwinn-Hardy, Katrina, Evidente, Virgilio Gerald H, Waters, Cheryl, Muenter, Manfred D, Hardy, John
Format: Article
Language:English
Subjects:
Adult
Anticonvulsants. Antiepileptics. Antiparkinson agents
Antiparkinson Agents - therapeutic use
Antiparkinson Agents - toxicity
Biological and medical sciences
Disease Progression
Drug therapy
Humans
Levodopa - therapeutic use
Levodopa - toxicity
Medical research
Medical sciences
Middle Aged
Neuropharmacology
Parkinson Disease - drug therapy
Parkinson Disease - genetics
Parkinson Disease - mortality
Parkinson's disease
Pharmacology. Drug treatments
Survival Analysis
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The putative toxicity of levcodopa has long been debated. Loevodopa is the mainstay of therapy for Parkinson's disease. Sometimes treatment is delayed because of fear of toxicity.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(99)01398-7